knowledge -WSS

knowledge

author：leisure time 2025-08-15 15:53:11 Page View：687

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted
Next article： After affirmative action ruling, medical educators look to 'holistic review'

focus

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Teladoc has a new CEO, but challenges remain the same

AdobeVirtualcarecompanyTeladochasanewchiefexecutiveofficerfollowingtheabruptdepartureofitslongtimele

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

NIH tests clinical research in primary care with $30 million program

TheNIH'snewprimarycareresearchnetworkaimstoimproverepresentationinclinicalscience.AdobeFormanyAmeric

knowledge

explore

focus

NIH tests clinical research in primary care with $30 million program